发明名称 |
Method of treating airway diseases with β-adrenergic inverse agonists |
摘要 |
The use of β-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a β-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol. |
申请公布号 |
US9539221(B2) |
申请公布日期 |
2017.01.10 |
申请号 |
US200410574677 |
申请日期 |
2004.10.08 |
申请人 |
EGB ADVISORS, LLC;INVION, INC. |
发明人 |
Bond Richard A. |
分类号 |
A61K39/395;A61K31/138;A61K31/137;A61K31/192;A61K31/403;A61K31/46;A61K31/47;A61K31/522;A61K31/56 |
主分类号 |
A61K39/395 |
代理机构 |
Ditthavong & Steiner, P.C. |
代理人 |
Ditthavong & Steiner, P.C. |
主权项 |
1. A method for treatment of pulmonary airway disease in a subject suffering from pulmonary airway disease comprising chronically administering a therapeutically effective amount of a β-adrenergic inverse agonist to the subject to treat the pulmonary airway disease by action of inverse agonism to promote long-term upregulation of the population of β-adrenergic receptors upon chronic administration of the β-adrenergic inverse agonist, wherein the β-adrenergic inverse agonist exhibits inverse agonist activity at the β2 receptor of bronchial tissue, wherein the β-adrenergic inverse agonist is selected from the group consisting of nadolol, bupranolol, butoxamine, carazolol, ICI-118,551, levobunolol, metoprolol, and timolol, and wherein such chronic administration requires increasing dosages over time. |
地址 |
Wilmington DE US |